My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About Us
Plans & Pricing

Cigna (CI) Receives a Hold from Leerink Partners

Leerink Partners analyst Jim Kelly reiterated a Hold rating on Cigna (CIResearch Report) on October 8. The company’s shares closed last Monday at $203.93.

According to, Kelly is a 1-star analyst with an average return of -1.7% and a 27.3% success rate. Kelly covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Atea Pharmaceuticals, and Aligos Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $267.53 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $272.81 and a one-year low of $160.37. Currently, Cigna has an average volume of 2.02M.

Based on the recent corporate insider activity of 115 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1792, Cigna Corporation is a Connecticut-based global health services company, which provides insurance and related products and services. It operates through the following segments: Health Services, Integrated Medical, International Markets, and Group Disability and Other.

Read More on CI: